HC Wainwright & Co. Reiterates Neutral on Inhibikase Therapeuticsto Neutral
Benzinga Newsdesk 1 year ago
NewsReiterationAnalyst Ratings
HC Wainwright & Co. analyst Edward White reiterates Inhibikase Therapeutics (NASDAQ:IKT) from Neutral to Neutral.
HC Wainwright & Co. analyst Edward White reiterates Inhibikase Therapeutics (NASDAQ:IKT) from Neutral to Neutral.